Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA – Get Free Report) gapped up before the market opened on Monday after BMO Capital Markets raised their price target on the stock from $20.00 to $35.00. The stock had previously closed at $16.99, but opened at $17.50. BMO Capital Markets currently has an outperform rating on the stock. Centessa Pharmaceuticals shares last traded at $17.16, with a volume of 32,375 shares trading hands.
A number of other analysts have also recently commented on the company. Morgan Stanley upped their price target on Centessa Pharmaceuticals from $8.00 to $11.00 and gave the stock an “equal weight” rating in a research report on Friday, June 21st. Jefferies Financial Group raised their target price on shares of Centessa Pharmaceuticals from $13.00 to $19.00 and gave the stock a “buy” rating in a research note on Wednesday, September 11th. Oppenheimer reiterated an “outperform” rating and issued a $14.00 price target on shares of Centessa Pharmaceuticals in a research report on Wednesday, August 14th. Finally, Guggenheim raised their price objective on shares of Centessa Pharmaceuticals from $20.00 to $24.00 and gave the company a “buy” rating in a research report on Wednesday, September 11th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $20.60.
Check Out Our Latest Stock Report on Centessa Pharmaceuticals
Insider Activity at Centessa Pharmaceuticals
Institutional Investors Weigh In On Centessa Pharmaceuticals
Several large investors have recently added to or reduced their stakes in the stock. Jump Financial LLC purchased a new position in Centessa Pharmaceuticals during the fourth quarter worth $114,000. Trexquant Investment LP purchased a new position in shares of Centessa Pharmaceuticals during the fourth quarter valued at approximately $114,000. Franklin Resources Inc. grew its stake in shares of Centessa Pharmaceuticals by 34.1% during the fourth quarter. Franklin Resources Inc. now owns 1,115,817 shares of the company’s stock valued at $8,882,000 after buying an additional 283,469 shares during the last quarter. Platinum Investment Management Ltd. lifted its stake in shares of Centessa Pharmaceuticals by 12.9% during the 4th quarter. Platinum Investment Management Ltd. now owns 381,083 shares of the company’s stock worth $3,033,000 after acquiring an additional 43,539 shares during the last quarter. Finally, Octagon Capital Advisors LP boosted its holdings in Centessa Pharmaceuticals by 333.2% during the 4th quarter. Octagon Capital Advisors LP now owns 2,060,100 shares of the company’s stock valued at $16,398,000 after acquiring an additional 1,584,500 shares during the period. 82.01% of the stock is owned by institutional investors.
Centessa Pharmaceuticals Stock Performance
The firm has a market capitalization of $1.72 billion, a P/E ratio of -11.96 and a beta of 1.44. The company has a debt-to-equity ratio of 0.27, a current ratio of 13.29 and a quick ratio of 13.29. The firm has a 50-day moving average price of $11.76 and a two-hundred day moving average price of $10.48.
Centessa Pharmaceuticals (NASDAQ:CNTA – Get Free Report) last announced its quarterly earnings data on Tuesday, August 13th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.02). On average, analysts forecast that Centessa Pharmaceuticals plc will post -1.61 EPS for the current fiscal year.
Centessa Pharmaceuticals Company Profile
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its pipeline products include SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders.
Recommended Stories
- Five stocks we like better than Centessa Pharmaceuticals
- Investing in Travel Stocks Benefits
- Congress Members Are Buying These 3 Hot Stocks
- What is Put Option Volume?
- Moderna’s Recent Drop: 4 Reasons Bulls See Opportunity
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- 3 Undervalued Stocks That Are Too Cheap to Ignore Right Now
Receive News & Ratings for Centessa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Centessa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.